Saroglitazar

A PPARα and PPARγ dual agonist (EC50s = 0.65 and 3,000 pM, respectively); decreases serum triglyceride, free fatty acid, and glucose levels in a db/db mouse model of diabetes at 0.01-3 mg/kg; increases insulin sensitivity in an oral glucose challenge at 1 mg/kg; reverses palmitic acid-induced decreases in SOD1, SOD2, GPX, and catalase expression and increases in TNF-α, IL-1β, and IL-6 expression in HepG2 cells at 10 µM; decreases hepatic inflammation and steatosis in a mouse model of NASH induced by a choline-deficient high-fat diet at 3 mg/kg